We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 11 investment: Withheld
DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £145,000
Studio Pictures Limited is a UK based production company that specialises in the development of high-quality British film and TV projects. The company's interest predominantly lies within the British film and television industry that can be created within budget ranging from £1 million - £15 million. The company has established relationships with studio houses such as Warner Bros., Sony Pictures and Lionsgate and aims to build upon projects that can be made into a franchise. Their production, A Steet Cat Named Bob, went on to be distributed by Sony Pictures in the UK and had a Royal Premiere in London. Studio Pictures Limited will consider putting up to a maximum of 20% of the budget for each project as equity, on a case by case basis, subject to company reserves. With the proceeds, the company will grow and scale the business. It will become a tenant at Twickenham Studios in West London and look to profitable emerging markets, i.e. streaming, animation and interactive movies to become one of the leading UK production companies.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.

Pitch Rated

30%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Active Food Systems, trading as Synergy Grill, has developed and patented innovative and commercial cooking technology for the food and hospitality industry. Its ‘Fat Atomising Grill' makes cleaning quick and easy while delivering cost savings through a 59% reduction in fuel consumption. The company has sold 2000+ units of the grill to entities like Whitbread, Greene King, Marriott, Radisson and Marstons among others. Synergy Grill asserts that its performance in the first half of the year has been profitable despite COVID-19. They have contracts with reputed organisations like Whitbread and Marstons have generated revenues of £970,000. The company is in conversation with over 50 pubs and restaurants including product trials with Nandos, Weatherspoons and Mitchell Butler that are interested in its product. It will use the investment to grow its business across different verticals.
days to go: Expired investment: £316,488
Aveqia is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. These experiences are run by Michelin star trained chefs.
days to go: Expired investment: £100,000
Aveqia London is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. Aveqia gives clients or colleagues the opportunity to work together to prepare and consume cuisine.
days to go: Expired investment: £100,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph